Anna O Ermakova

Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.

2 papers in the library · 115 citations · publishing 2022-2024

Papers

A narrative synthesis of research with 5-MeO-DMT.

Journal of psychopharmacology (Oxford, England) March 1, 2022 Anna O Ermakova, Fiona Dunbar, James Rucker et al. 83 citations

5-MeO-DMT is a short-acting psychedelic tryptamine found in nature and used historically for spiritual purposes. This review of existing literature covers its pharmacology, chemistry, metabolism, epidemiological studies, and reported effects. 5-MeO-DMT acts as a serotonergic agonist with highest affinity for 5-HT1A receptors. Animal model studies exist, but human clinical studies are lacking. Epidemiological data indicate it induces profound alterations in consciousness, including mystical experiences, with potential beneficial long-term effects on mental health and well-being. Its short duration, relative lack of visual effects, and higher rates of ego-dissolution make it a potentially useful addition to the psychedelic pharmacopoeia, warranting further clinical exploration with appropriate precautions.

DOI: 10.1177/02698811211050543 Full text 5-methoxy-n N-dimethyltryptamine Classic psychedelic Hallucinogen +10

Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants.

Journal of psychopharmacology (Oxford, England) August 1, 2024 James Jonathan Rucker, Claire Roberts, Mathieu Seynaeve et al. 32 citations

A new intranasal formulation of 5-MeO-DMT, called BPL-003, was tested in 44 healthy people who had never used psychedelics. Doses up to 12 mg were well tolerated, with no serious side effects; common mild effects included nasal discomfort, nausea, headache, and vomiting. The drug was absorbed quickly, reaching peak levels in about 8–10 minutes, and cleared from the body in under 27 minutes. Higher doses produced stronger subjective drug intensity and mystical experiences, with 60% of participants reporting a 'complete mystical experience' at 10 and 12 mg. The rapid onset and short duration suggest potential for treating conditions like depression.

DOI: 10.1177/02698811241246857 Full text 5-MEO-DMT Treatment-resistant depression Pharmacodynamics Pharmacokinetics +7